Efficiency and compliance are sometimes presented as competing priorities in pharmaceutical manufacturing.
One side wants faster processes, less paperwork and lower costs. The other wants controls, documentation and assurance.
That is an increasingly outdated way of looking at quality.
A mature Pharmaceutical Quality System should be capable of improving efficiency while protecting patients and maintaining compliance.
The real target for pharmaceutical organisations is not simply “doing less”.
It is removing activities that add little value while retaining, and strengthening, the controls that genuinely manage risk.
Compliance Is Not an Excuse for Inefficiency
Many pharmaceutical processes have developed incrementally over years.
A procedure is introduced after an inspection. Another approval is added following a deviation. Additional signatures are introduced because of one historic event.
Individually, each decision may once have made sense.
Over time, however, organisations can accumulate processes that are more complicated than the risk requires.
Forms contain duplicated information. CAPAs require multiple low-value approvals. Employees enter the same data into several systems. Low-risk changes follow almost identical workflows to high-risk ones.
The result is not necessarily better quality.
In some cases, overly complex systems can create new problems by directing skilled QA resources towards administration rather than critical thinking.
Lean Quality Starts With Risk Management
ICH Q9(R1) provides an important foundation for improving quality processes because it reinforces the use of quality risk management across pharmaceutical operations.
A lean approach should therefore begin by asking:
Where does this process protect the patient, the product or the validated state?
Activities that directly manage significant risks should remain appropriately robust.
Activities that exist mainly because “we have always done it this way” deserve closer examination.
This does not mean removing controls indiscriminately.
It means matching control to risk.
A low-impact document correction, for example, should not necessarily consume the same level of organisational effort as a significant manufacturing-process change affecting a critical quality attribute.
Reduce the Deviation Burden at Source
One of the most effective forms of lean quality is preventing deviations rather than processing them more quickly.
Quality teams should examine recurring events and ask what they reveal about underlying systems.
If operators repeatedly make the same documentation error, further retraining may not be the complete solution.
The real issue might be:
- an unnecessarily complicated SOP;
- poor system design;
- confusing forms;
- an ineffective user interface;
- excessive manual transcription; or
- unclear process ownership.
A mature quality organisation should therefore measure more than deviation closure times.
It should consider whether the same types of deviations continue to occur.
An organisation closing 1,000 deviations quickly is not necessarily performing better than one preventing hundreds of those deviations from occurring.
Use CAPA More Selectively
CAPA systems are another common source of quality-system congestion.
Not every deviation requires a formal corrective and preventive action.
Overuse of CAPA can create large backlogs, dilute attention and make truly significant actions harder to manage.
Risk-based processes should help distinguish between isolated low-risk events and systemic issues requiring formal corrective action.
The objective is not to avoid CAPAs.
It is to ensure CAPA resources are concentrated where meaningful improvements are required.
Remove Duplicate Data
Digital transformation offers substantial opportunities for waste reduction.
Manual transcription between laboratory systems, manufacturing systems, spreadsheets and an eQMS consumes time while also introducing error risk.
Well-designed integrations can simultaneously improve efficiency and data integrity.
Similarly, dashboards can give QA teams earlier visibility of overdue investigations, recurring deviations or emerging trends without requiring employees to manually compile reports.
The technology itself, however, should not become the objective.
Automation should remove unnecessary activity while maintaining suitable control over GxP processes.
Simplify Documentation Without Weakening It
More documentation does not automatically mean stronger compliance.
Effective documentation should be clear, accurate and usable.
Long procedures containing unnecessary detail may make compliance harder if operators struggle to identify the steps that actually matter.
Lean documentation asks whether information is:
- required;
- useful;
- duplicated elsewhere;
- written for the people performing the task; and
- capable of supporting consistent execution.
Simplification can therefore be a quality improvement rather than simply an efficiency exercise.
Focus QA Resources Where Expertise Adds Value
Qualified QA professionals are a valuable and finite resource.
If experienced specialists spend large proportions of their day performing low-risk administrative checks, organisations may have less capacity for complex investigations, process improvement, supplier oversight and risk assessment.
Risk-based workflows can help address this.
Some activities genuinely require detailed independent QA review.
Others may be handled through standardised workflows, trained process owners or automated controls.
The distinction needs to be deliberate and scientifically justified.
ICH Q10 supports continual improvement throughout the product lifecycle and places quality risk management and knowledge management at the heart of an effective pharmaceutical quality system.
Lean Does Not Mean Cutting Corners
This distinction is fundamental.
Lean quality should never mean reducing environmental monitoring because it is expensive, shortening an investigation to meet a KPI or removing controls without understanding their purpose.
In sterile manufacture, for example, the revised EU GMP Annex 1 places significant emphasis on Quality Risk Management and an organisation’s Contamination Control Strategy.
A lean approach in that environment should make those controls more effective, not weaker.
Better facility design, automation, barrier technology, improved process understanding and smarter data analysis can reduce intervention and waste while simultaneously improving contamination control.
Mature Quality Systems Look Beyond Compliance
FDA’s Quality Management Maturity programme also reflects increasing attention on organisations that develop quality practices beyond minimum CGMP expectations.
FDA links mature quality management with improved process performance, product quality, reliable supply and proactive continual improvement.
That is ultimately where lean quality and pharmaceutical compliance meet.
The goal should not be to identify the minimum amount of quality activity an organisation can get away with.
It should be to maximise the value of every quality activity it performs.
Reducing duplication, preventing repeat deviations, simplifying unnecessarily complicated processes and applying resources according to risk can create faster and more effective pharmaceutical operations.
Done correctly, efficiency and compliance do not compete.
They strengthen one another.